Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating of "Moderate Buy" by Analysts

Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) has received an average rating of "Moderate Buy" from the eleven ratings firms that are currently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $26.00.

A number of research analysts recently commented on the company. Morgan Stanley dropped their price target on Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating for the company in a research note on Tuesday, February 18th. Bank of America cut their target price on Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a research note on Wednesday, February 19th. Wedbush reiterated an "outperform" rating and issued a $33.00 price target on shares of Arcus Biosciences in a research note on Wednesday. Barclays lowered their price target on Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating for the company in a report on Wednesday, April 23rd. Finally, HC Wainwright upgraded Arcus Biosciences from a "neutral" rating to a "buy" rating and lifted their target price for the company from $18.00 to $24.00 in a research report on Wednesday, February 26th.

Insider Activity

In other news, CEO Terry J. Rosen acquired 19,800 shares of Arcus Biosciences stock in a transaction dated Thursday, February 27th. The shares were bought at an average cost of $10.18 per share, with a total value of $201,564.00. Following the purchase, the chief executive officer now owns 2,554,160 shares in the company, valued at $26,001,348.80. This trade represents a 0.78 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Yasunori Kaneko bought 20,000 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were purchased at an average cost of $10.06 per share, with a total value of $201,200.00. Following the purchase, the director now directly owns 28,400 shares of the company's stock, valued at $285,704. The trade was a 238.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 12.30% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Gilead Sciences Inc. acquired a new stake in shares of Arcus Biosciences in the 4th quarter valued at about $447,610,000. Boxer Capital Management LLC acquired a new stake in Arcus Biosciences in the fourth quarter valued at approximately $23,857,000. Braidwell LP bought a new stake in shares of Arcus Biosciences during the fourth quarter valued at approximately $11,943,000. Millennium Management LLC raised its position in shares of Arcus Biosciences by 277.1% during the fourth quarter. Millennium Management LLC now owns 924,369 shares of the company's stock worth $13,764,000 after purchasing an additional 679,267 shares during the period. Finally, Jacobs Levy Equity Management Inc. bought a new position in shares of Arcus Biosciences in the 4th quarter worth $6,928,000. 92.89% of the stock is owned by institutional investors.

Arcus Biosciences Stock Performance

NYSE RCUS traded down $0.16 on Friday, reaching $8.37. The stock had a trading volume of 240,307 shares, compared to its average volume of 826,055. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. The company has a market cap of $886.26 million, a P/E ratio of -2.66 and a beta of 0.88. The firm has a fifty day moving average of $8.42 and a two-hundred day moving average of $12.49. Arcus Biosciences has a 1-year low of $6.50 and a 1-year high of $18.98.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.12). Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The company had revenue of $28.00 million during the quarter, compared to the consensus estimate of $38.61 million. During the same quarter last year, the firm posted ($0.05) earnings per share. The company's quarterly revenue was down 80.7% on a year-over-year basis. On average, equities research analysts anticipate that Arcus Biosciences will post -3.15 EPS for the current year.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.